Pat W. Whitworth

Articles by Pat W. Whitworth

102 Novel Prognostic and Predictive Locoregional Biosignature for Risk Stratification of Early-Stage Hormone Receptor–Positive Breast Cancer

ByCharlotta Wadsten,Karuna Mittal,Pat W. Whitworth,Chirag Shah, MD,Frank Vicini, MD,Naamit Gerber,Melissa Krystel-Whittemore,Clayton C. Yates,Balasubramanyam Karanam,Walter Bell,Charles E. Cox, MS, FACS,Abigail Beard,Geza Acs,Steven C. Shivers,David J. Dabbs,Jess Savala,Mark Mentrikoski,Troy Bremer

April 14th 2025

104 Identification of Ductal Carcinoma In Situ Patients With Low-Risk Clinicopathology Who Benefit From Radiation Therapy With and Without Endocrine Therapy After Breast-Conserving Surgery Assessed With the 7-Gene Biosignature

ByPat W. Whitworth,Chirag Shah, MD,Frank Vicini, MD,Rachel Rabinovitch, MD,Julie A. Margenthaler, MD,Fredrik Warnberg,Micheal Leo,Sheila Weinmann,G. Bruce Mann,David J. Dabbs,Jess Savala,Steven C. Shivers,Karuna Mittal,Troy Bremer

April 12th 2025

66 A Comparative Analysis of Changes in Treatment Recommendation for Black and White Patients With Ductal Carcinoma In Situ Using a 7-Gene Predictive Biosignature: Analysis of the PREDICT Study

ByPat W. Whitworth,Steven C. Shivers,Chirag Shah, MD,Rakesh Patel,Charles E. Cox, MS, FACS,Karuna Mittal,Troy Bremer

May 5th 2024

38 Comparing Risk Stratification and Radiotherapy Benefit for Patients With DCIS Using a 7-Gene Biosignature as Compared to a Clinicopathologic Nomogram

ByJulie A. Margenthaler, MD,Karuna Mittal,Frank A. Vicini, MD,Chirag Shah, MD,Rachel Rabinovitch, MD,Pat W. Whitworth,Brian Czerniecki,David J. Dabbs,G. Bruce Mann,Fredrik Wärnberg,Sheila Weinmann,Michael Leo,Steven C. Shivers,Troy Bremer

April 26th 2023

39 7-Gene Predictive Biosignature Improves Risk Stratification for Breast Ductal Carcinoma In Situ Patients Compared to Clinicopathologic Criteria, Identifying a Low-Risk Group Not Clinically Benefiting from Adjuvant Radiotherapy

ByRachel Rabinovitch, MD,Frank A. Vicini, MD,Chirag Shah, MD,Julie A. Margenthaler, MD,Brian Czerniecki,Pat W. Whitworth,David J. Dabbs,G. Bruce Mann,Fredrik Wärnberg,Sheila Weinmann,Michael Leo,Jess Savala,Steven C. Shivers,Karuna Mittal,Troy Bremer

April 26th 2023

40 Characterization of Recurrence Risk After Lumpectomy and Radiotherapy in HER2-Positive Ductal Carcinoma in Situ of the Breast Using a 7-Gene Predictive Biosignature: Implications for the NSABP-B43 Trial Results

ByFrank A. Vicini, MD,Chirag Shah, MD,Rachel Rabinovitch, MD,Pat W. Whitworth,Julie A. Margenthaler, MD,Brian Czerniecki,David J. Dabbs,Sheila Weinmann,Michael Leo,G. Bruce Mann,Fredrik Wärnberg,Jess Savala,Steven C. Shivers,Karuna Mittal,Troy Bremer

April 26th 2023

41 Changes in Treatment Recommendation for Patients With Ductal Carcinoma In Situ Using a 7-Gene Predictive Biosignature: Analysis of the PREDICT Study

ByPat W. Whitworth,Steven C. Shivers,Chirag Shah, MD,Rakesh Patel,Karuna Mittal,Troy Bremer,Charles E. Cox, MS, FACS

April 26th 2023

37 The Routine Use of Bioimpedance Spectroscopy Measurements in the Clinic as a Surrogate for Bone Mineral Content in Oncology Patients: Practical Application of the SOZO Device

BySteven C. Shivers,Pat W. Whitworth,Rachel Rabinovitch, MD,Frank Vicini, MD,Chirag Shah, MD,Fredrik Wärnberg,G. Bruce Mann,Karuna Mittal,Troy Bremer

May 6th 2022

39TiP The PREDICT Registry: A Prospective Registry Study to Evaluate the Effect of a Predictive Assay on Treatment Decisions in Patients withDCIS Following Breast Conserving Therapy

BySteven C. Shivers,Pat W. Whitworth,Rakesh Patel,Troy Bremer,Charles E. Cox, MS, FACS

May 6th 2022

38 Clinicopathological Risk Factors, Poorly Stratified Baseline Risk, and RT Benefit Compared to DCISionRT in Patients With Ductal Carcinoma in Situ

ByPat W. Whitworth,Rachel Rabinovitch, MD,Frank A. Vicini, MD,Chirag Shah, MD,Fredrik Wärnberg,G. Bruce Mann,Steven C. Shivers,Karuna Mittal,Troy Bremer

May 6th 2022

Pat W. Whitworth

Articles by Pat W. Whitworth

102 Novel Prognostic and Predictive Locoregional Biosignature for Risk Stratification of Early-Stage Hormone Receptor–Positive Breast Cancer

104 Identification of Ductal Carcinoma In Situ Patients With Low-Risk Clinicopathology Who Benefit From Radiation Therapy With and Without Endocrine Therapy After Breast-Conserving Surgery Assessed With the 7-Gene Biosignature

66 A Comparative Analysis of Changes in Treatment Recommendation for Black and White Patients With Ductal Carcinoma In Situ Using a 7-Gene Predictive Biosignature: Analysis of the PREDICT Study

38 Comparing Risk Stratification and Radiotherapy Benefit for Patients With DCIS Using a 7-Gene Biosignature as Compared to a Clinicopathologic Nomogram

39 7-Gene Predictive Biosignature Improves Risk Stratification for Breast Ductal Carcinoma In Situ Patients Compared to Clinicopathologic Criteria, Identifying a Low-Risk Group Not Clinically Benefiting from Adjuvant Radiotherapy

40 Characterization of Recurrence Risk After Lumpectomy and Radiotherapy in HER2-Positive Ductal Carcinoma in Situ of the Breast Using a 7-Gene Predictive Biosignature: Implications for the NSABP-B43 Trial Results

41 Changes in Treatment Recommendation for Patients With Ductal Carcinoma In Situ Using a 7-Gene Predictive Biosignature: Analysis of the PREDICT Study

37 The Routine Use of Bioimpedance Spectroscopy Measurements in the Clinic as a Surrogate for Bone Mineral Content in Oncology Patients: Practical Application of the SOZO Device

39TiP The PREDICT Registry: A Prospective Registry Study to Evaluate the Effect of a Predictive Assay on Treatment Decisions in Patients withDCIS Following Breast Conserving Therapy

38 Clinicopathological Risk Factors, Poorly Stratified Baseline Risk, and RT Benefit Compared to DCISionRT in Patients With Ductal Carcinoma in Situ

Latest Updated Articles

Trending on CancerNetwork

ASH 2025: Key Anticipated Updates in the Leukemia Landscape

ASH 2025: Which Presentations Will Move the Multiple Myeloma Needle?

Real-World Elranatamab Maintains Responses in Elderly, Frail R/R Multiple Myeloma

Fixed-Duration Venetoclax Combos Show Noninferior PFS to Ibrutinib in CLL

MRD May Predict Survival in Induction Chemotherapy AML Trials